The Inflammatory Bowel Disease Disability Index (IBD-DI) has recently been developed for patients with Crohn's disease (CD) and ulcerative colitis (UC).
Dr Burisch and colleagues assessed the severity of disability and associated factors using the IBD-DI, and review the validity of the IBD-DI as a tool.
The research team performed a systematic review of cross-sectional studies.
Patients included had UC or CD and were classified as active, in remission, or needing surgery, biological and/or steroid treatment.
|Patients with active disease had higher disability rates |
|Alimentary Pharmacology & Therapeutics|
The researchers included studies assessing disability using the IBD-DI and that were captured by electronic and manual searches.
The possibility of bias was evaluated with the Newcastle-Ottawa Scale.
The research team included 9 studies with 3167 patients.
Comparatively, patients with active disease had higher disability rates than those in remission, while patients on biological treatment had lower disability rates than those receiving corticosteroid treatment.
The research team found that disease activity and unemployment were associated factors.
The IBD-DI scored “good” for internal consistency, “fair” to “excellent” for intra-rater reliability and “excellent” for inter-rater reliability.
Construct validity was “moderately strong” to “very strong” and structural validity was found to be mainly unidimensional.
The team noted that IBD-DI had excellent responsiveness, while its interpretability was only useful on a group level.
Dr Burisch's team concludes, "This systematic review and meta-analysis found a significant association between disease activity, treatment received and disability, although significant heterogeneity was found."
"The IBD-DI is reliable and valid, but further studies are needed to measure its interpretability."